Viagra not effective for foetal growth complications: Study

Image
IANS London
Last Updated : Dec 09 2017 | 12:50 PM IST

Anti-impotency Viagra drug used to prevent serious growth complications affecting babies in the womb is ineffective, finds a study.

Foetal growth restriction, commonly called intrauterine growth restriction (IUGR), is a complicated pregnancy condition, in which a baby does not grow to normal weight.

The condition develops when the placenta fails to develop correctly as a result of poor flow of blood through it.

Sildenafil, sold under the brand name Viagra causes blood vessels to relax and has been used for many years for the treatment of male erectile problems.

Viagra had emerged as a potential management option in the treatment of IUGR.

Improving the blood supply to the placenta should improve the growth and well-being of the IUGR baby, said researchers from the University of Liverpool.

However, the study, published in The Lancet Child and Adolescent Health, revealed that when Sildenafil was administered to pregnant women with a severely growth-restricted foetus, it did not prolong pregnancy, improve survival, or reduce short-term neonatal morbidity.

"Sadly the use of this drug in this way was ineffective," said Zarko Alfirevic, Professor at the varsity.

"However, as part of our continuing research, we are now monitoring the growth and development of the babies who participated in the trial to learn even more about this disease and its implications with a view to help us to identify possible treatment options in the future," Alfirevic added.

For the study, the team recruited 135 women who were less than 30 weeks into their pregnancies with an IUGR baby. Of these, 70 of the women were prescribed Sildenafil and 65 women a placebo.

--IANS

rt/in/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 09 2017 | 12:46 PM IST

Next Story